

## S 3466

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020

**Congress:** 116 (2019–2021, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Mar 12, 2020

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Mar 12, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/senate-bill/3466>

### Sponsor

**Name:** Sen. McSally, Martha [R-AZ]

**Party:** Republican • **State:** AZ • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Jones, Doug [D-AL]	D · AL		Mar 12, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 12, 2020

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 4597	Related bill	<b>Oct 2, 2019:</b> Referred to the Subcommittee on Health.

## **Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020 or the ACCESS for Biosimilars Act of 2020**

This bill temporarily eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

The bill's provisions apply to products that are furnished during the five-year period beginning on January 1, 2021, or the date on which the product is first marketed, whichever is later.

### **Actions Timeline**

---

- **Mar 12, 2020:** Introduced in Senate
- **Mar 12, 2020:** Read twice and referred to the Committee on Finance.